Skip to search formSkip to main contentSkip to account menu

XR9576

Known as: XR 9576 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Purpose: P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a… 
2010
2010
ObjectiveXR9576 (tariquidar) is an anthranilic acid derivative and potent P-glycoprotein (P-gp) inhibitor. XR9576 has undergone… 
Highly Cited
2009
Highly Cited
2009
Purpose: P-glycoprotein (Pgp) antagonists have had unpredictable pharmacokinetic interactions requiring reductions of… 
Highly Cited
2007
Highly Cited
2007
Summary:  Purpose: A biotechnologic breakthrough for the study of drug permeability across the blood–brain barrier (BBB) would be… 
Highly Cited
2003
Highly Cited
2003
99mTc-sestamibi, a substrate of the multidrug transporter P-glycoprotein (Pgp), has been used as a functional imaging agent for… 
Highly Cited
2003
Highly Cited
2003
Highly Cited
2001
Highly Cited
2001
The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug resistance (MDR). This protein acts as… 
Highly Cited
2000
Highly Cited
2000
XR9576 is a novel inhibitor of P-glycoprotein (P-gp) that has been shown to reverse P-gp-dependent multidrug-resistance in tumor…